Low-dose anti-VEGFR2 therapy promotes anti-tumor immunity in lung adenocarcinoma by down-regulating the expression of layilin on tumor-infiltrating CD8+T cells
Biaolong Yang(Shanghai Changzheng Hospital), Yuan‐Sheng Zang(Shanghai Changzheng Hospital)
Cited by 18